1 / 15

2nd Quebec Conference on Therapeutic Resistance in Cancer

2nd Quebec Conference on Therapeutic Resistance in Cancer. Bienvenue !!!!!. Network and Partners. Members 80 members from Montréal, Québec City and Sherbrooke. Coalition Priorité Cancer (advocacy group). Government FRSQ (research) MDEIE (economic dev.) MSSS (health). Q-CROC.

truly
Télécharger la présentation

2nd Quebec Conference on Therapeutic Resistance in Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue!!!!!

  2. Network and Partners Members 80 members from Montréal, Québec City and Sherbrooke Coalition Priorité Cancer (advocacy group) Government FRSQ (research) MDEIE (economic dev.) MSSS (health) Q-CROC Hospitals Universities Pharma (Pfizer, Sanofi and many others)

  3. Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Standard First-Line Therapy in Patients with Metastatic Colorectal Cancer (Q-CROC-01) Needle core biopsies of liver metastasis at D0 and at acquired resistance Blood samples collected and banked during treatment Biopsy-driven study in Non-Hodkins Lymphoma (NHL) using rituximab in combination with a drug involved in epigenetic modifications (Q-CROC-02) Lymph node biopsies D0, D15 and optional at 24 hrs PBMC isolation at D0 and D15 The genomics and proteomics of Triple Negative Breast Cancer drug resistant breast cancer(Q-CROC-03) Neoadjuvant: Biopsy: breast before treatment and at surgery Metastatic: Biopsy: liver, skin, lung, pleura; before and after treatment Ongoing Q-CROC Research Projects

  4. ER+ luminal A ER+ luminal B HER2+ Triple negative (ER-PR-HER2-), basal-like normal Breast cancer gene expression array phenotyping can guide therapy: This is only a first step.......

  5. Predictive markers: WHY? Estrogen receptor: the oldest target and tumor marker Tamoxifen: discovered in 1970s Efficacy in ER+ breast cancers adjuvant Resistance Prognostic, biologic factors Prognostic, biologic factors

  6. Predictive markers: WHY? HERCEPTIN: effective in breast cancer patients with ERBB2 amplification (approx 15-25% breast cancer patients) Romond E et al. N Engl J Med 2005;353:1673-1684 Kaplan-Meier Estimates of Disease-free Survival (Panel A) and Overall Survival (Panel B) $ 50000/year

  7. Burning questions: WHO can be spared unnecessary treatment? WHO will predictably not benefit? HOW can we overcome resistance? Focus on therapeutic resistance in the metastatic setting

  8. FOCUS: Metastatic disease • Metastases are ultimately the lethal element • They are either initially or inevitably become resistant • New treatments are almost always studied in this setting • There are opportunties for biology discovery (e.g. discordance between primary and metastatic tumors, etc.) • Limited number of annotated biobanks of metastatic tumors linked to specific therapies

  9. FOCUS: Therapeutic resistance • Clinically resistance is a ‘hard endpoint’…what is stable disease? • Scientific opportunities • The biology of intrinsic resistance vs. acquired resistance • ? Stem cells • Novel mechanisms, novel cross-talk between pathways • Modifications of drugs to overcome resistance • Potential new chemosensitizers • Diagnostic tests

  10. Personalized medicine Because technology to facilitate it is rapidly developing; Because it is scientifically and conceptually appealing; Because it may be the only way to afford new targeted agents It is best for the patients, since humility requires us to recognize serious limitations in our current approach

  11. Thanks to sponsors • Canadian Institutes for Health Research: conference grant • Gold sponsor: Roche Canada • Platinum Sponsor: Astra Zeneca • And many others

More Related